View Article

Abstract

Effective documentation control is a cornerstone of Good Manufacturing Practices (GMP) and is a regulatory imperative across pharmaceutical and healthcare industries. This review explores key principles of Good Documentation Practices (GDP), detailing the essential components of document creation, management, and maintenance. Core areas include proper formatting, accurate record-keeping, handling of electronic documentation, error correction protocols, and long-term data preservation. High-quality documentation reflects the operational integrity and compliance standards of a pharmaceutical organization. The paper emphasizes that whether maintained on paper or electronically, documentation must uphold characteristics such as being attributable, legible, traceable, permanent, contemporaneous, original, and accurate. Robust documentation not only supports the development, approval, and lifecycle management of pharmaceutical products but also plays a pivotal role in ensuring data reliability and regulatory transparency. Recommendations provided aim to strengthen site-level documentation systems, fostering a culture of quality and accountability.

Keywords

GDP, Electronic documentations, Accurate record.

Introduction

Good Manufacturing Practices (GMP) are fundamental to the pharmaceutical and healthcare sectors, where the accuracy and reliability of documentation significantly influence product quality and regulatory compliance. Documentation is not merely a procedural formality it is a legal and ethical obligation that underpins traceability, consistency, and accountability across all stages of product development and lifecycle management.

GMP requires structured documentation systems that include specifications, manufacturing and packaging instructions, batch records, and validation protocols. These records are essential for demonstrating compliance with regulatory standards, and they allow for the traceability of each batch for a defined retention period commonly at least one year beyond expiration. Such documentation helps ensure that every product is manufactured and controlled according to standards appropriate for its intended use.[1]

Good Documentation Practices (GDP), as defined by the World Health Organization (WHO), are critical components of quality assurance. GDP encompasses all methods of generating, maintaining, correcting, and securing data to safeguard its integrity throughout a product's lifecycle. Whether documents are handwritten or electronic, they must be attributable, legible, traceable, permanent, contemporaneously recorded, original, and accurate.[2]

Clearly structured and verified documents help prevent errors, particularly in operations such as formulation, testing, packaging, and record-keeping. Unlike verbal communication, which can be ambiguous and unverifiable, written procedures like Standard Operating Procedures (SOPs), Master Formula Records, and batch documentation create a definitive audit trail.

Regulatory authorities like the U.S. FDA have codified expectations for documentation through frameworks like 21 CFR 211.180(e), which emphasize the necessity of written records for assessing drug quality. Compliance with these standards is mandatory for pharmaceutical companies and their collaborators, and non-compliance can lead to regulatory actions.

This paper presents an in-depth review of GDP, with focus areas including:

  • Fundamentals of document creation and management
  • Classification and layout best practices
  • Record completion and retention
  • Electronic records handling
  • Correction protocols and secure storage
  • Impact of country-specific regulations and use of ERP/SAP systems

Through this exploration, the aim is to underscore the role of GDP in building a reliable and compliant quality management system one that safeguards both product integrity and patient safety.[1-2]

Principles of Good Documentation Practices (GDP)

Good Documentation Practices (GDP) form the foundation of quality assurance and are integral to compliance with Good Manufacturing Practices (GMP). These principles govern the creation, control, and preservation of documents that reflect the manufacturing, testing, and distribution activities of medicinal products.

Documentation in pharmaceutical environments may take diverse forms including handwritten records, electronic systems, and photographic media. Regardless of format, all documentation should be clearly defined within the organization’s Quality Management System (QMS), which must outline standards for content, structure, approval, retention, and disposal.[3]

The primary objectives of GDP are to:

  • Establish control over activities impacting product quality
  • Enable monitoring and traceability across the product lifecycle
  • Ensure accuracy and completeness in data recording
  • Support regulatory audits and inspections through a robust paper trail

To achieve these goals, the QMS should provide:

  • Clear instructions and procedures that promote consistency and reduce ambiguity
  • Mechanisms for recording observations and maintaining traceable records
  • Training and tools that support a shared understanding of documentation standards

There are two principal categories of documentation:

  • Instructional Documents: Include SOPs, protocols, specifications, and guidelines. These must be error-free, approved, and written in a format that is human-readable and consistently interpretable.
  • Records and Reports: Include batch records, logbooks, analytical results, and audit reports. These must be maintained accurately to demonstrate adherence to GMP protocols.

Effective GDP also requires:

  • Suitable controls to ensure data integrity and prevent tampering
  • Consistent availability and legibility of documents, both printed and digital
  • Defined media and formats that allow readable rendering of stored information

At its core, GDP ensures that all documentation whether physical or electronic is secure, attributable, accurate, contemporaneous, and traceable, thereby upholding product quality and regulatory compliance.[4]

Types of Documents

Figure 1: Types of Documents

  • Specifications Define the quality standards for materials and finished products. Include product identity, formulation, acceptance limits, and storage conditions.
  • Master Production Records (MPR) Provide detailed instructions for manufacturing each product. Ensure consistency and regulatory compliance across batches.
  • Batch Production Records (BPR) Document actual production data for each batch. Capture materials used, equipment details, process parameters, and yields.
  • Standard Operating Procedures (SOPs) Authorized documents outlining step-by-step instructions for routine activities like sampling, equipment cleaning, and deviation handling.
  • Validation Master Plan (VMP) A high-level document that outlines the strategy and scope of validation across systems and processes.
  • User Requirement Specifications (URS) Define the functional and performance requirements for equipment or systems before procurement or design.
  • Qualification Documents (DQ, IQ, OQ, PQ) Used to verify and validate equipment performance:
    • DQ – Design Qualification
    • IQ – Installation Qualification
    • OQ – Operational Qualification
    • PQ – Performance Qualification
  • Certificates of Analysis (CoA) Reports confirming that materials or products meet specified testing criteria.
  • Test Methods Describe detailed analytical procedures to assess quality attributes and performance parameters.
  • Laboratory Control Records Track sample testing, results, reagent usage, and calibration activities.
  • Deviation Reports Document non-conformances, root cause analyses, and corrective actions.
  • Technical Agreements Define responsibilities between partners or contractors involved in manufacturing or testing.
  • Audit Plans and Reports Outline inspection schedules and findings related to compliance and quality systems.
  • Confidentiality Agreements Legal documents protecting sensitive data shared between parties.
  • Job Descriptions and Organograms Define personnel roles, responsibilities, and reporting structure within the organization.
  • Training Records Track employee qualifications and completed training modules related to GMP tasks.
  • Facility Layout Plans and HVAC Schematics Ensure proper infrastructure for cleanroom design, airflow systems, and environmental control.
  • Environmental Monitoring Records Capture microbial and particulate counts in controlled areas to support sterility assurance.
  • Logbooks and Worksheets Record operational data, maintenance logs, and routine checks to support traceability.[5]

Documentation Lifecycle

The documentation lifecycle encompasses creation, review, approval, distribution, storage, revision, and archiving. Each stage ensures traceability, compliance, and accountability. Control mechanisms must be in place to maintain data integrity throughout the lifecycle.[6]

Figure 2: Documentation Life Cycle

Key Elements of Good Documentation Practice (GDP)

GDP relies on principles that make records accurate, legible, timely, and traceable. Essential elements include:

  • Proper formatting and version control
  • Authorized access and signatures
  • Documented corrections with reason, date, and initials
  • Adherence to SOPs for handling, updating, and archiving[7]

Electronic Documentation and Data Integrity

With the rise of digital platforms, electronic documentation is governed by data integrity principles such as ALCOA+:

  • Attributable, Legible, Contemporaneous, Original, Accurate
  • Plus: Complete, Consistent, Enduring, Available

Systems must validate electronic records for authenticity, security, audit trails, and backup protocols.[8]

Common Documentation Errors and Deviations

Errors frequently cited by regulatory bodies include:

  • Use of pencil or white-out
  • Undated corrections or missing explanations
  • Obscured original entries
  • Lack of audit trails or incomplete sample logs Preventive measures include robust training, SOP enforcement, and regular audits.[9]

Training and Awareness for GDP Compliance

Personnel must undergo regular training to ensure understanding of GDP principles. Key focus areas:

  • Correct error handling
  • Document entry protocols
  • Importance of contemporaneous records Training should be role-specific and reinforced through assessments and refresher courses.

GDP in Regulatory Audits and Inspections[10]

Inspectors evaluate GDP as part of GMP audits. Areas of scrutiny include:

  • Completeness of batch records
  • Legibility and traceability of entries
  • Handling of deviations and corrections Documentation lapses often lead to citations, impacting regulatory trust and product approvals.

Challenges in Implementation of GDP

Organizations face several hurdles:

  • Resistance to change in documentation culture
  • Integration of paper and digital systems
  • Maintaining consistency across global operations Effective change management and harmonized SOPs can mitigate these challenges.[11]

Recent Trends and Innovations in Documentation

Innovative developments include:

  • AI-powered audit trail tracking
  • Blockchain for record authenticity
  • Cloud-based documentation platforms. These innovations enhance accessibility, security, and real-time monitoring of data.

CONCLUSION

This review has underscored the critical importance of good documentation practices (GDP) within pharmaceutical quality assurance systems. Each document type from specifications to batch records not only reflects regulatory requirements but also plays a vital role in building a transparent, traceable, and controlled manufacturing environment. GDP ensures that all procedures, decisions, and quality standards are faithfully recorded, facilitating regulatory audits and supporting the integrity of product development and lifecycle management.

Effective documentation is far more than recordkeeping; it is a strategic quality tool that safeguards compliance with Good Manufacturing Practice (GMP), strengthens data reliability, and enables continuous improvement. By integrating GDP principles into the daily operations of pharmaceutical organizations through structured procedures, digital systems, training programs, and routine document reviews companies can foster a culture of accountability and excellence.

In essence, the consistent application of GDP transforms documentation into a powerful framework for regulatory confidence, patient safety, and sustainable product quality.

REFERENCES

  1. Patel, K. T. and Chotai, N.P., (2008). Pharmaceutical GMP: Past, Present, and Future--a Re view. Pharmazie.;63(4):251-5.
  2. Hargreaves, P. (2007). “Good Manufacturing Practice in the Control of Contamination” in Deyner, S.P. and Baird, R.M. (eds.), Guide to Microbiological Control in Pharmaceuticals and Medical Devices, 2nd edition, CRC Press, Boca Raton, FL, pp121-142.
  3. Sandle Tim. Good Documentation Practices. Journal of validation Technology. Oct 2014; Volume 20. Page No.1.
  4. Todd, J. I. (2007). Good Manufacturing Practice for Immunological Veterinary Medicinal Prod ucts. Rev Sci Tech.;26(1):135-45.
  5. Snell JJ, Brown DF, Roberts C, editors. Quality assurance: principles and practice in the microbiology laboratory. Public Health Laboratory Service; 1999. 2.
  6. EudraLex; The Rules Governing Medicinal Products in the European Union Volume - 4; Good Manufacturing Practices Part I Basic Requirements for Medicinal Products. http://ec.europa.eu/enterprise/sectors/pharmaceuticals/documents/eudralex/vol-4/index_en.htm ,2010
  7. Mehta Binny, Hemangini Makwana, Pinak Patel, Krunal Detholia. A Concise Review on "Good Documentation Practice". JPSBR .02 March 2019; ISSN NO. 2271-3681, Page No 24.
  8. Sandle Tim. Good Documentation Practices. Journal of validation Technology. Oct 2014; Volume 20. Page No.1.
  9. Bhattacharya  Joymalya. Good Documentation Practice (Gap): Coordinate Regulatory Requirements in Pharmaceutical Manufacturing Industry. IOSK-JPBS. Sep-Oct 2014; Volume 9. Issue 5 Ver VI. Page No.24.
  10. Göbel, C., Baier, D., Ruhfus, B. and Hundt, F. (2009). GCP Inspections in Germany and Eu rope Following the Implementation of the Di rective 2001/20/ec, Ger Med Sci. 31;7: doc01. Doi: 10.3205/000060.
  11. Sandle, T. and Lamba, S. S. (2012). “Effectively Incorporating Quality Risk Management into Quality Systems". in Saghee, M.R..(ed.). Achiev ing Quality and Compliance Excellence in Phar maceuticals: A Master Class GMP Guide, New Delhi: Business Horizons, pp89-128.
  12. Bolton, F.J. and Howe, S.A. (1999). “Documen tation in the Laboratory” in Snell, J.J.S., Brown, D.F.J., and Roberts, C. Quality Assurance: Prin ciples and Practice in the Microbiology Labora tory, pp19-28.

Reference

  1. Patel, K. T. and Chotai, N.P., (2008). Pharmaceutical GMP: Past, Present, and Future--a Re view. Pharmazie.;63(4):251-5.
  2. Hargreaves, P. (2007). “Good Manufacturing Practice in the Control of Contamination” in Deyner, S.P. and Baird, R.M. (eds.), Guide to Microbiological Control in Pharmaceuticals and Medical Devices, 2nd edition, CRC Press, Boca Raton, FL, pp121-142.
  3. Sandle Tim. Good Documentation Practices. Journal of validation Technology. Oct 2014; Volume 20. Page No.1.
  4. Todd, J. I. (2007). Good Manufacturing Practice for Immunological Veterinary Medicinal Prod ucts. Rev Sci Tech.;26(1):135-45.
  5. Snell JJ, Brown DF, Roberts C, editors. Quality assurance: principles and practice in the microbiology laboratory. Public Health Laboratory Service; 1999. 2.
  6. EudraLex; The Rules Governing Medicinal Products in the European Union Volume - 4; Good Manufacturing Practices Part I Basic Requirements for Medicinal Products. http://ec.europa.eu/enterprise/sectors/pharmaceuticals/documents/eudralex/vol-4/index_en.htm ,2010
  7. Mehta Binny, Hemangini Makwana, Pinak Patel, Krunal Detholia. A Concise Review on "Good Documentation Practice". JPSBR .02 March 2019; ISSN NO. 2271-3681, Page No 24.
  8. Sandle Tim. Good Documentation Practices. Journal of validation Technology. Oct 2014; Volume 20. Page No.1.
  9. Bhattacharya  Joymalya. Good Documentation Practice (Gap): Coordinate Regulatory Requirements in Pharmaceutical Manufacturing Industry. IOSK-JPBS. Sep-Oct 2014; Volume 9. Issue 5 Ver VI. Page No.24.
  10. Göbel, C., Baier, D., Ruhfus, B. and Hundt, F. (2009). GCP Inspections in Germany and Eu rope Following the Implementation of the Di rective 2001/20/ec, Ger Med Sci. 31;7: doc01. Doi: 10.3205/000060.
  11. Sandle, T. and Lamba, S. S. (2012). “Effectively Incorporating Quality Risk Management into Quality Systems". in Saghee, M.R..(ed.). Achiev ing Quality and Compliance Excellence in Phar maceuticals: A Master Class GMP Guide, New Delhi: Business Horizons, pp89-128.
  12. Bolton, F.J. and Howe, S.A. (1999). “Documen tation in the Laboratory” in Snell, J.J.S., Brown, D.F.J., and Roberts, C. Quality Assurance: Prin ciples and Practice in the Microbiology Labora tory, pp19-28.

Photo
Omkar Gosavi
Corresponding author

Department of Pharmaceutical Quality Assurance,Samarth Institute of Pharmacy Belhe, Pune-Maharashtra, India

Photo
Dr. Sachin Datkhile
Co-author

Department of Pharmaceutical Quality Assurance,Samarth Institute of Pharmacy Belhe, Pune-Maharashtra, India

Photo
Komal Aher
Co-author

Department of Pharmaceutical Quality Assurance,Samarth Institute of Pharmacy Belhe, Pune-Maharashtra, India

Photo
Divya Deshmukh
Co-author

Department of Pharmaceutical Quality Assurance,Samarth Institute of Pharmacy Belhe, Pune-Maharashtra, India

Photo
Sahil Patel
Co-author

Sharadchandra Pawar College of Pharmacy, Dumbaarwadi

Photo
Bhakti Gurav
Co-author

Department of Pharmaceutical Quality Assurance,Samarth Institute of Pharmacy Belhe, Pune-Maharashtra, India

Photo
Komal Gaikwad
Co-author

Department of Pharmaceutical Quality Assurance,Samarth Institute of Pharmacy Belhe, Pune-Maharashtra, India

Omkar Gosavi, Dr. Sachin Datkhile, Komal Aher, Divya Deshmukh, Sahil Patel, Bhakti Gurav, Komal Gaikwad, Good Documentation Practices (GDP) in Pharmaceutical Quality Assurances, Int. J. of Pharm. Sci., 2025, Vol 3, Issue 9, 669-675. https://doi.org/10.5281/zenodo.17063364

More related articles
AI in Drug Delivery...
Saqlain Mirasaheb Mujawar, Sadiya Dastagir Ugare, ...
In-Silico Design, Synthesis and Antiprolifertive E...
K. P. Swathi, Mary Mathew, Gayathri, ...
Related Articles
A Comprehensive Review: The Purposes and Targeting Locations of Silica-Based Nan...
Mayur S. Tekade, Nitin W. Pawar, Poonam D. Awaghate, Jagdish V. Manwar, Anand Asawa, ...
Role of LC-MS in Proteomics...
M. Prathibha Bharathi, K. Malleshwari, D. Vijaya Durga, T. Bhavana, B. Madhavi, ...
Nanocrystalline Albendazole: Fabrication, Stability, and Anthelmintic Efficacy E...
Ashwini Inganal, Arjun Uppar, Sangamesh Sakri, Megha Patil, Akash Hiremath, ...
Pyridopyrimidines In Medicinal Chemistry: A Comprehensive Review of Their Therap...
Dr. S. Sreeja, Abin Alex Binoy, S. R. Anchu, V. S. Athira, L. Venkitachalam, K. Nandhini, ...